2 hours ago
The UK announced the suspension of clinical trials of the Oxford/AstraZeneca vaccine against children. At the same time, the British drug regulatory agency is investigating the connection between the vaccine and the rare blood clot problem that occurs after adult vaccination.
Professor Andrew Pollard of the University of Oxford told the BBC that the experiment itself had no safety issues, but the scientists on his team were waiting for further news.
Approximately 300 volunteers signed up to participate in the trial.
Earlier British Prime Minister Johnson called on the public to be vaccinated when invited.
Over 31.6 million people in the UK have received the first dose and 5.4 million people have received the second dose.
There are currently two vaccines available to the public in the UK. They are Oxford/AstraZeneca and Pfizer/BioNtech vaccines. The third vaccine from Moderna has also been approved for use in the UK.
The Oxford/AstraZeneca vaccine trial for children started in February this year is intended to assess whether the vaccine can produce a strong immune response in children between 6 and 17 years of age.
Earlier, an official of the European Medicines Agency (EMA) spoke in his personal capacity and stated that the vaccine appeared to be linked to thrombosis.
After confirming the suspension of the vaccine test in children, Professor Pollard said: “Although there is no safety issue when testing the vaccine in children, I think it is a kind of protection for children. Before proceeding further, we are working Waiting for more information on the investigation of rare cases of thrombosis/thrombocytopenia in adults by the British Medical and Health Regulatory Agency (MHRA).”
The European Medicines Agency and the National Medical and Health Regulatory Agency are expected to announce the latest investigations in the next few days.
The European Medicines Agency said its safety committee “has not yet reached a conclusion and is currently investigating.”
The British Medical and Health Regulatory Authority said that the benefits of the vaccine still outweigh the disadvantages.
Analysis: the benefits and risks of vaccination
Nick Triggle BBC Health Correspondent
From vaccines to paracetamol (paracetamol), which relieves pain and reduces fever, all medicines have the potential to cause serious side effects. After being vaccinated with seasonal flu vaccine, there is about a one in a million chance of suffering from neurological disorders Guillain-Barré syndrome.
So the real question is: Are the benefits of the vaccine worth the risk?
Whether the vaccine is the cause of blood clots and death is still unproven. The data shows that one in every 2.5 million people vaccinated will die.
For people over 75 years of age, one in eight people infected with the new crown will die; for people in their 40s, one person will die for every 1,000 infections.
So on the surface, if you assume that you will be infected, the benefits of vaccination clearly outweigh the risks.
But now it is necessary to disclose information about these rare thrombosis patients. How old are they? Are you suffering from underlying diseases that induce thrombosis?
These will help risk control.
British and European regulators are expected to provide relevant investigation information in the next few days.
When visiting the AstraZeneca vaccine production plant earlier on Tuesday (April 6), British Prime Minister Johnson defended the vaccine.
“Regarding the Oxford/AstraZeneca vaccine (recommendation), the public had better listen to what our independent regulatory agency, the British Healthcare Regulatory Authority, said.” Johnson said that he had received the first dose of the vaccine. Continue to go out and receive the first and second shots of the vaccine.”
Johnson added: “The best result is to vaccinate everyone and get everyone out to get vaccinated. This is the key. This is also the top priority I advocate.”
Some countries have suspended the Oxford/AstraZeneca vaccine for young people, Germany has suspended injections for people under 60, and Canada has also suspended injections for people under 55.
The UK has confirmed an order for 457 million doses of the new crown vaccine, of which 100 million doses are from AstraZeneca. British Vaccine Minister Nadhim Zahawi (Nadhim Zahawi) said that the Modena vaccine will be deployed “around the third week of April.”
The British Medical and Health Regulatory Authority said that as of March 24 (including March 24), 30 rare thrombotic events have been discovered after 18.1 million doses of the vaccine have been injected. Of these 30 cases, 7 people have died.
But Dr. June Raine, the chief executive of the British regulatory agency, said, “The public should continue to vaccinate when they are invited. We are dealing with the very rare and special types of blood clots and low platelets that appear after the AstraZeneca vaccine. The situation undergoes a comprehensive and detailed review.”
“There has not yet been a decision to take any regulatory action.”
A member of the Joint Committee on Vaccination and Immunization, which provides recommendations for vaccine promotion to the British government, told the BBC News Night that relevant departments are taking this issue seriously, “We really need to find out the truth.”
In his personal capacity, Professor Adam Finn claimed that the suspension of children’s trials is a “precautionary measure” because they are waiting for clearer information, not because of any problems with the vaccine.
When asked whether his views on vaccines have changed in the past two weeks, Professor Finn said that the formation of thrombosis is related to the low number of platelets. At the same time, special attention should be paid to the lack of relevant case data of Pfizer vaccine.
“These two things do raise serious questions of possibility, which may involve an association. We need to take it very seriously and understand it more clearly,” he said. “If Pfizer vaccine has no such association Because of this, I didn’t even see any such cases. I am personally surprised by this. This is one of the reasons why we are concerned about this matter.”